134 related articles for article (PubMed ID: 28911087)
1. An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages.
Huber-Ruano I; Raventós C; Cuartas I; Sánchez-Jaro C; Arias A; Parra JL; Wosikowski K; Janicot M; Seoane J
Ann Oncol; 2017 Sep; 28(9):2278-2285. PubMed ID: 28911087
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas.
Papachristodoulou A; Silginer M; Weller M; Schneider H; Hasenbach K; Janicot M; Roth P
Clin Cancer Res; 2019 Dec; 25(23):7189-7201. PubMed ID: 31530630
[TBL] [Abstract][Full Text] [Related]
3. Biological Role and Therapeutic Targeting of TGF-β
Seystahl K; Papachristodoulou A; Burghardt I; Schneider H; Hasenbach K; Janicot M; Roth P; Weller M
Mol Cancer Ther; 2017 Jun; 16(6):1177-1186. PubMed ID: 28377490
[TBL] [Abstract][Full Text] [Related]
4. Berberine Suppresses Cell Motility Through Downregulation of TGF-β1 in Triple Negative Breast Cancer Cells.
Kim S; Lee J; You D; Jeong Y; Jeon M; Yu J; Kim SW; Nam SJ; Lee JE
Cell Physiol Biochem; 2018; 45(2):795-807. PubMed ID: 29414799
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of oncogenic transforming growth factor-β1 signaling by antisense oligonucleotides in oral squamous cell carcinoma.
Kim SG; Song JY
Oncol Rep; 2012 Aug; 28(2):539-44. PubMed ID: 22581233
[TBL] [Abstract][Full Text] [Related]
6. Treatment of transforming growth factor-beta-insensitive mouse Renca tumor by transforming growth factor-beta elimination.
Perry K; Wong L; Liu V; Park I; Zhang Q; Rejen V; Huang X; Smith ND; Jovanovic B; Lonning S; Teicher BA; Lee C
Urology; 2008 Jul; 72(1):225-9. PubMed ID: 18295867
[TBL] [Abstract][Full Text] [Related]
7. Naringenin prevents TGF-β1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation.
Zhang F; Dong W; Zeng W; Zhang L; Zhang C; Qiu Y; Wang L; Yin X; Zhang C; Liang W
Breast Cancer Res; 2016 Apr; 18(1):38. PubMed ID: 27036297
[TBL] [Abstract][Full Text] [Related]
8. Silibinin inhibits triple negative breast cancer cell motility by suppressing TGF-β2 expression.
Kim S; Han J; Jeon M; You D; Lee J; Kim HJ; Bae S; Nam SJ; Lee JE
Tumour Biol; 2016 Aug; 37(8):11397-407. PubMed ID: 26984157
[TBL] [Abstract][Full Text] [Related]
9. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.
Arteaga CL; Koli KM; Dugger TC; Clarke R
J Natl Cancer Inst; 1999 Jan; 91(1):46-53. PubMed ID: 9890169
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer.
Schlingensiepen KH; Jaschinski F; Lang SA; Moser C; Geissler EK; Schlitt HJ; Kielmanowicz M; Schneider A
Cancer Sci; 2011 Jun; 102(6):1193-200. PubMed ID: 21366804
[TBL] [Abstract][Full Text] [Related]
11. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
12. Specific inhibition of transforming growth factor-beta2 expression in human osteoblast cells by antisense phosphorothioate oligonucleotides.
Shen ZJ; Kim SK; Kwon OS; Lee YS; Moon BJ
Eur J Biochem; 2001 Apr; 268(8):2331-7. PubMed ID: 11298751
[TBL] [Abstract][Full Text] [Related]
13. An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.
Rausch MP; Hahn T; Ramanathapuram L; Bradley-Dunlop D; Mahadevan D; Mercado-Pimentel ME; Runyan RB; Besselsen DG; Zhang X; Cheung HK; Lee WC; Ling LE; Akporiaye ET
Anticancer Res; 2009 Jun; 29(6):2099-109. PubMed ID: 19528470
[TBL] [Abstract][Full Text] [Related]
14. Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β.
Parvani JG; Galliher-Beckley AJ; Schiemann BJ; Schiemann WP
Mol Biol Cell; 2013 Nov; 24(21):3449-59. PubMed ID: 24006485
[TBL] [Abstract][Full Text] [Related]
15. TGF-β2 antisense oligonucleotide enhances T-cell mediated anti-tumor activities by IL-2 via attenuation of fibrotic reaction in a humanized mouse model of pancreatic ductal adenocarcinoma.
Lee HK; Nam MW; Go RE; Koo J; Kim TH; Park JE; Choi KC
Biomed Pharmacother; 2023 Mar; 159():114212. PubMed ID: 36610224
[TBL] [Abstract][Full Text] [Related]
16. Effect of the abrogation of TGF-beta1 by antisense oligonucleotides on the expression of TGF-beta-isoforms and their receptors I and II in isolated fibroblasts from keloid scars.
Bran GM; Goessler UR; Schardt C; Hormann K; Riedel F; Sadick H
Int J Mol Med; 2010 Jun; 25(6):915-21. PubMed ID: 20428796
[TBL] [Abstract][Full Text] [Related]
17. Antisense TGF-beta2 immunotherapy for hepatocellular carcinoma: treatment in a rat tumor model.
Maggard M; Meng L; Ke B; Allen R; Devgan L; Imagawa DK
Ann Surg Oncol; 2001; 8(1):32-7. PubMed ID: 11206222
[TBL] [Abstract][Full Text] [Related]
18. Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF-β) Isoform mRNAs for the Treatment of Solid Tumors.
Jaschinski F; Korhonen H; Janicot M
Methods Mol Biol; 2015; 1317():137-51. PubMed ID: 26072406
[TBL] [Abstract][Full Text] [Related]
19. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
Lee Y; Vassilakos A; Feng N; Lam V; Xie H; Wang M; Jin H; Xiong K; Liu C; Wright J; Young A
Cancer Res; 2003 Jun; 63(11):2802-11. PubMed ID: 12782585
[TBL] [Abstract][Full Text] [Related]
20. Combined targeting of TGF-β1 and integrin β3 impairs lymph node metastasis in a mouse model of non-small-cell lung cancer.
Salvo E; Garasa S; Dotor J; Morales X; Peláez R; Altevogt P; Rouzaut A
Mol Cancer; 2014 May; 13():112. PubMed ID: 24884715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
